W
Winfried Häuser
Researcher at Technische Universität München
Publications - 389
Citations - 19998
Winfried Häuser is an academic researcher from Technische Universität München. The author has contributed to research in topics: Fibromyalgia & Chronic pain. The author has an hindex of 61, co-authored 361 publications receiving 15838 citations. Previous affiliations of Winfried Häuser include University of Duisburg-Essen.
Papers
More filters
Journal ArticleDOI
New treatment options for fibromyalgia: critical appraisal of duloxetine.
TL;DR: Two randomized, placebo-controlled trials have investigated the short-term safety and efficacy of duloxetine 60 mg/day and 120 mg/ day in patients suffering from FMS, and both dosages were superior to placebo in pain relief, and improvement in quality of life and depressive symptoms.
Journal ArticleDOI
Obesity, depression and hip pain.
Martin Schwarze,Winfried Häuser,Gabriele Schmutzer,Elmar Brähler,Nicholas A. Beckmann,Marcus Schiltenwolf +5 more
TL;DR: Hip pain is rarely the sole site of pain, and obesity and increased values on the depression scale are associated with disabling chronic hip pain.
Journal ArticleDOI
Meta-analyses of pain studies: What we have learned
Winfried Häuser,Thomas R. Tölle +1 more
TL;DR: It is demonstrated that pain responses in patients with chronic pain, following treatment, are not normally distributed but have a bimodal distribution with the majority of patients having either very little or very good pain relief.
Journal ArticleDOI
A comparison of the clinical features of fibromyalgia syndrome in different settings
Winfried Häuser,Werner Biewer,Mechthild Gesmann,Hedi Kühn-Becker,Frank Petzke,Hubertus von Wilmoswky,Jost Langhorst,Heide Glaesmer +7 more
TL;DR: A "funnel" is found between F MS-persons of the general population and FMS-patients of clinical settings, but not between patients of different levels of care.
Journal ArticleDOI
Langzeitopioidtherapie von nichttumorbedingten Schmerzen
TL;DR: One major concern of long-term opioid therapy (LTOT) for chronic noncancer pain (CNCP) is the risk of abuse of prescribed opioids.